Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reduction In Flights Hits Global Supply Chain

Global And European Bodies Call For Urgent Action Amid Coronavirus

Executive Summary

Urgent action is needed to reopen air freight routes so that the global off-patent industry can deliver critical medicines and supplies amid the coronavirus pandemic, international industry representatives have insisted.

You may also be interested in...



EU Industry Welcomes New Schengen Strategy’s Green Lanes

Planned reforms to the EU’s Schengen open border system that will allow for transport “green lanes” to be reactivated when necessary have been welcomed by off-patent industry association Medicines for Europe.

European Industry Played Key Role In Mitigating COVID-19

In the first part of an exclusive two-part interview, James Burt – Accord’s executive vice-president for Europe, the Middle East and North Africa – talks to Generics Bulletin about the key actions taken by the generics industry to mitigate the coronavirus pandemic, and the changed landscape that the off-patent arena can expect to see in future.

Australian Bodies Set Out Joint Position On Coronavirus

Australia’s off-patent industry association, the GBMA, and local brand organization Medicines Australia have set out their plans for collaborating on supplying essential medicines amid the coronavirus pandemic. The move follows a recent temporary authorization by local competition regulator the ACCC that will allow the bodies to work more closely together.

Related Content

Topics

UsernamePublicRestriction

Register

GB149743

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel